相关实验视频
Updated: Jan 9, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.3K
当代治疗中的心脏毒性:新的问题,机制和预防技术
Nirmala V Shinde1, Swarali A Pawar1, Sachin K Bhosale1
1SMBT College of Pharmacy, Dhamangaon, Tal: Igatpuri, Dist: Nashik, 422403 Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.
概括
了解药物诱导的心脏毒性机制是预防心力衰竭的关键. 本综述详细介绍了药物受体相互作用和风险因素,以提高药物治疗中的患者安全性.
科学领域:
- 心血管药理学心血管药理学
- 毒理学 毒理学 毒理学
- 药品安全 药品安全
背景情况:
- 心力衰竭是全球主要的健康问题.
- 药物诱导的心脏毒性对心血管健康构成重大风险.
- 了解药物受体相互作用对于患者的安全至关重要.
研究的目的:
- 系统地审查药物诱导心脏毒性的机制.
- 确定涉及的治疗剂和涉及的受体.
- 检查风险因素和当前的管理策略.
主要方法:
- 现有研究的系统文献审查.
- 对药物诱导的心脏损伤的临床数据的分析.
- 确定关键药物类别及其心脏毒性途径.
主要成果:
- 通常涉及的药物包括利多卡因,特拉斯图祖马布和环素.
- 特定的药物受体相互作用驱动心脏毒性作用.
- 各种风险因素使个人易患心脏损伤.
结论:
- 了解心脏毒性途径对于减少药物诱导的心脏损伤至关重要.
- 多学科的方法可以减轻心血管风险.
- 对心脏保护和早期诊断的持续研究至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Dysrhythmias VI: Management of Dysrhythmias
414
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
414
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Cardiopulmonary Resuscitation IV: Pharmacological Management
595
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
595

